Welcome to our dedicated page for Mineralys Therapeutics SEC filings (Ticker: MLYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mineralys Therapeutics, Inc. filings document the public-company disclosures of a biopharmaceutical issuer developing lorundrostat for hypertension and related comorbidities driven by dysregulated aldosterone. Form 8-K reports cover quarterly and annual financial results, corporate updates, Regulation FD disclosures, FDA acceptance of the lorundrostat New Drug Application, and clinical results from the Explore-OSA exploratory trial.
The filing record also includes proxy materials for annual meeting voting and stockholder procedures, along with material-event disclosures for capital-structure matters. These include common stock arrangements under an ATM Equity Offering Sales Agreement, registration-statement references, material agreements, and shareholder voting matters.
Mineralys Therapeutics insider David Rodman filed a Form 144 to sell 7,709 shares of common stock through Merrill Lynch on or about 01/13/2026, to be traded on NASDAQ. The shares come from an employee stock option exercise on the same date, using a broker-assisted cashless exercise.
The filing notes that common stock outstanding was 79,139,956 shares. Over the past three months, Rodman has reported several sales of Mineralys common stock, including 192,715 shares on 01/05/2026 for gross proceeds of 6749100.06 and 70,037 shares on 01/02/2026 for gross proceeds of 2511919.03. The signer represents that they are not aware of undisclosed material adverse information about the company.
Mineralys Therapeutics, Inc. shareholder David Rodman has filed a notice to sell 6,348 shares of common stock. The shares are to be sold on NASDAQ through Merrill Lynch at an aggregate market value of $205,142.99, with the sale expected around 01/12/2026. The issuer reports 79,139,956 common shares outstanding.
The 6,348 shares were acquired on 01/12/2026 through the exercise of employee stock options in a broker-assisted cashless exercise from Mineralys Therapeutics, Inc. In the past three months, David Rodman has also sold Mineralys common stock, including 10,369 shares on 10/15/2025 for $445,982.61, 70,037 shares on 01/02/2026 for $2,511,919.03, and 192,715 shares on 01/05/2026 for $6,749,100.06.
Mineralys Therapeutics stockholder Adam Levy has filed a notice to sell 10,758 shares of common stock through Merrill Lynch, with an aggregate market value of $345,722.93 on the NASDAQ. The filing notes 79,139,956 shares of common stock outstanding. The 10,758 shares to be sold were acquired on 01/10/2026 via vesting of a restricted stock unit award granted under the issuer’s equity compensation plan. Over the prior three months, Adam Levy sold 10,758 shares of common stock on 10/13/2025 for gross proceeds of $451,983.33 and 119,524 shares on 11/11/2025 for gross proceeds of $5,363,716.05.
Mineralys Therapeutics, Inc. insider plans another stock sale under Rule 144. A person identified as Jon Congleton has filed to sell 16,236 shares of Mineralys common stock through Merrill Lynch on or about 01/12/2026 on the NASDAQ, with an indicated aggregate market value of $529,639.50. These shares were acquired on 01/10/2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan.
The notice also reports prior sales of Mineralys common stock during the past three months by the same seller, including 15,100 shares on 10/13/2025 for gross proceeds of $644,326.47 and 200,000 shares on 11/11/2025 for gross proceeds of $9,088,502.77. The filing lists 79,139,956 Mineralys common shares outstanding, providing context for the size of the planned sale.
Mineralys Therapeutics, Inc. insider David Rodman has filed a notice to sell 2,170 shares of common stock through Merrill Lynch on or about 01/09/2026 on the NASDAQ, with an aggregate market value of $72,195.90. These shares were acquired the same day via a broker-assisted cashless exercise of employee stock options. The filing also lists prior sales over the past three months, including 192,715 shares sold on 01/05/2026 for $6,749,100.06, 70,037 shares sold on 01/02/2026 for $2,511,919.03, and 10,369 shares sold on 10/15/2025 for $445,982.61. Shares of Mineralys Therapeutics outstanding were 79,139,956 around the time of the planned sale.
Mineralys Therapeutics Chief Medical Officer Rodman David Malcom reportedmultiple stock option exercises and related share sales in early January 2026. On January 2, 2026, he exercised options for 10,053, 3,629, 9,347, 20,168 and 24,193 shares of common stock at exercise prices of $1.08, $15.44, $10.20, $16.00 and $14.25, respectively, then sold 70,037 shares at a weighted-average price of $35.8656.
On January 5, 2026, he exercised additional options for 28,038, 10,121, 26,069, 53,630 and 67,473 shares at the same exercise prices, and sold 139,245 shares at a weighted-average price of $34.8275 and 53,470 shares at a weighted-average price of $35.5256. Following the last reported transaction, he directly owned 61,804 common shares, which includes 680 shares purchased under the 2023 Employee Stock Purchase Plan that were not previously reported. All transactions were effected under a Rule 10b5-1 trading plan adopted on October 6, 2025.
Mineralys Therapeutics (MLYS) reported that its Chief Executive Officer and director exercised stock options for 24,082 shares of common stock on 11/21/2025 at an exercise price of $0.54 per share.
Following this transaction, the CEO directly holds 655,387 shares of Mineralys common stock. The filing also clarifies that the option’s exercise price was previously shown as $0.53 per share due to a rounding error in an earlier Form 3, and notes that the option vested 25% on March 12, 2022, with the remainder vesting in 36 substantially equal monthly installments.
Mineralys Therapeutics, Inc. (MLYS) reported an insider transaction by a major shareholder group associated with Catalys Pacific. On 11/20/2025, an indirect holder reported the sale of 1,000,000 shares of Mineralys common stock at $43.35 per share, coded as an "S" transaction, which indicates a sale.
After this transaction, the reporting entities collectively reported 7,903,838 shares of Mineralys common stock beneficially owned on an indirect basis. The filing identifies the reporting persons as including a director and a 10% owner, with the shares held of record by Catalys Pacific Fund, LP and controlled through its general partner structure. The related entities and Brian Taylor Slingsby state that they may be deemed to have voting and investment power over these shares but disclaim beneficial ownership except to the extent of any pecuniary interest.
Mineralys Therapeutics (MLYS) Form 4: CFO and Secretary reported option exercises and share sales on 11/11/2025. He exercised options for 20,547 shares at $10.2, 34,414 at $16, 44,079 at $14.25, and 6,613 at $15.44. Same day, he executed multiple open-market sales, including 38,900 shares at a weighted-average price of $45.9277 and 32,718 at $46.8848, with other sales reported at weighted-average prices between $41.6522 and $46.8848.
Following the transactions, he directly beneficially owned 19,396 shares. The filing also notes that since his last ownership report, 83,598 shares were transferred to an ex-spouse pursuant to a domestic relations order.
Mineralys Therapeutics, Inc. (MLYS) reported insider activity on a Form 4. The company’s Chief Executive Officer and director sold 200,000 shares of common stock on 11/11/2025 in multiple transactions at weighted‑average prices that include $41.6395, $42.3095, $43.4959, $45.2003, $45.8335, and $46.8862. Footnotes disclose execution price ranges spanning $41.0500 to $47.4191 for the respective trades.
After these sales, the reporting person beneficially owns 631,305 shares, held directly. This filing lists the transactions as open‑market sales with weighted‑average pricing and provides to interested parties the availability of detailed trade‑by‑trade breakdowns upon request.